Increasing efficacy and safety of treatments of patients with well-differentiated thyroid carcinoma by measuring body retentions of 131I
JC Sisson, BL Shulkin, S Lawson - Journal of Nuclear Medicine, 2003 - Soc Nuclear Med
There is no consensus on the amount of 131I for treatment of patients with well-differentiated
thyroid carcinoma; usual amounts vary widely. Body retention of 131I has been shown to be …
thyroid carcinoma; usual amounts vary widely. Body retention of 131I has been shown to be …
Practical Dosimetry of 131I in Patients with Thyroid Carcinoma
JC Sisson - Cancer Biotherapy and Radiopharmaceuticals, 2002 - liebertpub.com
Radioiodine treatments of patients with well-differentiated thyroid carcinoma have generally
been safe and beneficial. Safety can be ensured while efficacy is increased through …
been safe and beneficial. Safety can be ensured while efficacy is increased through …
Percent 131I Uptake and Post-Therapy 131I Scans: Their Role in the Management of Thyroid Cancer
JC Reynolds - Thyroid, 1997 - liebertpub.com
This short review focuses on two questions commonly asked about 131I therapy of thyroid
cancer. The first relates to radiation dosimetry. What percentage of 131I uptake is needed for …
cancer. The first relates to radiation dosimetry. What percentage of 131I uptake is needed for …
74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (ie it does not cause stunning) in differentiated thyroid cancer
IR McDougall - Nuclear medicine communications, 1997 - journals.lww.com
SUMMARY Altogether, 147 scintiscans, completed 48–72 h after 74 MBq 131 I, were
compared with scintiscans obtained on average 7.8 days after therapeutic doses of 131 I …
compared with scintiscans obtained on average 7.8 days after therapeutic doses of 131 I …
131I effective half-life and dosimetry in thyroid cancer patients
H Remy, I Borget, S Leboulleux… - Journal of Nuclear …, 2008 - Soc Nuclear Med
131I treatment in thyroid cancer patients may induce side effects, including extrathyroidal
cancer and leukemia. There are still some uncertainties concerning parameters that may …
cancer and leukemia. There are still some uncertainties concerning parameters that may …
Utility of the radioiodine whole-body retention at 48 hours for modifying empiric activity of 131-iodine for the treatment of metastatic well-differentiated thyroid …
D Van Nostrand, F Atkins, S Moreau, M Aiken… - Thyroid, 2009 - liebertpub.com
Background: Dosimetry has been used to help identify when empiric dosages of 131-I
treatment for suspected metastatic well-differentiated thyroid carcinoma (WDTC) may be …
treatment for suspected metastatic well-differentiated thyroid carcinoma (WDTC) may be …
Thyroid carcinoma with high levels of function: treatment with 131I
JC Sisson, JE Carey - Journal of Nuclear Medicine, 2001 - Soc Nuclear Med
In some patients with well-differentiated thyroid carcinoma, dosimetry is necessary to avoid
toxicity from therapy and to guide prescription of the administered activity of radioiodine …
toxicity from therapy and to guide prescription of the administered activity of radioiodine …
Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients.
HR Maxon 3rd, EE Englaro, SR Thomas… - Journal of nuclear …, 1992 - europepmc.org
For almost five decades, 131I treatment of thyroid cancer has been based empirically on
administered activity rather than on actual radiation doses delivered. In 1983, we defined …
administered activity rather than on actual radiation doses delivered. In 1983, we defined …
Biological dosimetry in patients treated with iodine-131 for differentiated thyroid carcinoma
R M'kacher, JD Legal… - The Journal of …, 1996 - search.proquest.com
Iodine-131 for Differentiated Thyroid Carcinoma Page 1 Biological Dosimetry in Patients Treated
with Iodine-131 for Differentiated Thyroid Carcinoma R. M’Kacher, JD Legal, M. Schlumbcrger …
with Iodine-131 for Differentiated Thyroid Carcinoma R. M’Kacher, JD Legal, M. Schlumbcrger …
What is the role of 1100 MBq (< 30 mCi) radioiodine 131I in the treatment of patients with differentiated thyroid cancer?
M Van Wyngaarden, IR McDougall - Nuclear medicine …, 1996 - journals.lww.com
Based on pre-therapy whole-body 131 I scintiscans showing only residual thyroid, 64
patients with differentiated thyroid cancer were treated with 1100 MBq (< 30 mCi) 131 I as …
patients with differentiated thyroid cancer were treated with 1100 MBq (< 30 mCi) 131 I as …
相关搜索
- thyroid cancer radioiodine 131i
- thyroid carcinoma treatment with 131i
- efficacy and safety treatments of patients
- thyroid carcinoma efficacy and safety
- treatment of patients radioiodine 131i
- thyroid cancer treatment of patients
- thyroid carcinoma high levels
- practical dosimetry 131i in patients
- high levels treatment with 131i
- thyroid carcinoma practical dosimetry
- thyroid carcinoma 131i in patients
- thyroid carcinoma treatments of patients
- thyroid carcinoma safety of treatments
- thyroid carcinoma biological dosimetry
- thyroid cancer 131i scans